Top

Published in:

01-09-2009

Chemoembolization of hepatic malignancy

Authors: Carin F. Gonsalves, Daniel B. Brown

Published in: Abdominal Radiology | Issue 5/2009

Abstract

Treatment of primary and secondary hepatic malignancies with transarterial chemoembolization represents an essential component of interventional oncology. This article discusses patient selection, procedure technique, results, and complications associated with transarterial chemoembolization.

Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954;30:969–977PubMed

Liapi E, Georgiades CC, Hong K, et al. Transcatheter arterial chemoembolization: current technique and future promise. Tech Vasc Interv Radiol 2007; 10(1):2–11PubMedCrossRef

Kim W, Clark T, Baum RA, et al. Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 2001;12 (8):965–968PubMedCrossRef

Patel S, Tuite CM, Mondschein JI, Soulen MC Effectiveness of an aggressive antibiotic regimen for chemoembolization in patients with previous biliary intervention. J Vasc Interv Radiol 2006;17(12):1931–1934PubMed

Geschwind JH, Kauchik S. Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors. J Vasc Interv Radiol 2002; 13:1163–1166PubMedCrossRef

Berger DH, Carrasco CH, Hohn DC, et al. Hepatic artery chemoembolization or embolization for primary and metastatic liver tumors: post-treatment management and complications. J Surg Oncol 1995; 60:116–121PubMedCrossRef

Brown DB, Fundakowski CE, Lisker-Melman M, et al. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2004; 15:1209–1218PubMedCrossRef

Georgiades CS, Liapi E, Frangakis C, et al. Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization. J Vasc Interv Radiol 2006;17(10):1619–1624PubMed

Reed RA, Teitelbaum GP, Daniels JR, et al. Prevalence of infection following hepatic chemoembolization with crosslinked collagen with administration of prophylactic antibiotics. J Vasc Interv Radiol 1994;5:367–371PubMedCrossRef

10.

Ryan JM, Ryan BM, Smith TP. Antibiotic prophylaxis in interventional radiology. J Vasc Interv Radiol 2004;15:547–556PubMed

11.

Gupta S, Yao JC, Ahrar K, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 2003;9:261–267PubMedCrossRef

12.

Brown KT, Koh BY, Brody LA, et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol 1999;10:397–403PubMedCrossRef

13.

Chung J, Park J, Han J, et al. Transcatheter oily chemoembolization of the inferior phrenic artery in hepatocellular carcinoma: the safety and potential therapeutic role. J Vasc Interv Radiol 1998; 9:495–500PubMedCrossRef

14.

Tajima T, Honda H, Kuroiwa T, et al. Pulmonary complications after hepatic artery chemoembolization or infusion via the inferior phrenic artery for primary liver cancer. J Vasc Interv Radiol 2002; 13:893–900PubMedCrossRef

15.

Arora R, Soulen M, Haskal Z. Cutaneous complications of hepatic chemoembolization via extrahepatic collaterals. J Vasc Interv Radiol 1999; 10:1351–1356PubMedCrossRef

16.

Leung DA, Goin JE, Sickles C, et al. Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol 2001; 12:321–326PubMedCrossRef

17.

Chen M, Li J, Zhang Y, et al. High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol 2002;8(1):74–78PubMed

18.

Higashi S, Tabata N, Kondo KH, et al. Size of lipid microdroplets effects results of hepatic arterial chemotherapy with an anticancer agent in water-in-oil-in-water emulsion to hepatocellular carcinoma. J Pharmacol Exp Ther 1999; 289:816–819PubMed

19.

Sasaki Y, Imaoka S, Kasugai H, et al. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 1987; 60:1194–1203PubMedCrossRef

20.

Higuchi T, Kikuchi M, Okazaki M. Hepatocellular carcinoma after transcatheter hepatic arterial embolization:a histopathologic study of 84 resected cases. Cancer 1994; 73:2259–2267PubMedCrossRef

21.

Takayasu K, Arii S, Matsuo N, et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR 2000; 175:699–704PubMed

22.

Kubota K, Hisa N, Nishikawa T, et al. Evaluation of hepatocellular carcinoma after treatment with transcatheter arterial chemoembolization: comparison of Lipiodol-CT, power Doppler sonography, and dynamic MRI. Abdom Imaging 2001; 26:184–190PubMedCrossRef

23.

Chopra S, Dodd GD, Chintapalli KN, et al. Tumor recurrence after radiofrequency thermal ablation of hepatic tumors: spectrum of findings on dual phase contrast-enhanced CT. AJR 2001;177:381–387PubMed

24.

Barazani Y, Hiatt JR, Tong MJ, Busuttil RW Chronic viral hepatitis and hepatocellular carcinoma. World J Surg 2007; 31:1243–1248PubMedCrossRef

25.

El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Int Med 2000; 160:3227–3230CrossRef

26.

Rilling WS, Drooz A. Multidisciplinary management of hepatocellular carcinoma. J Vasc Interv Radiol 2002; 13:S259–S263PubMedCrossRef

27.

Geschwind JH. Chemoembolization for hepatocellular carcinoma: where does the truth lie? J Vasc Interv Radiol 2002; 13:991–994PubMedCrossRef

28.

Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164 –1171PubMedCrossRef

29.

Llovet J, Real MI, Montana X, et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002; 359:1734–1739PubMedCrossRef

30.

Cheng B, Jia C, Liu C, et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm. a randomized controlled trial. JAMA 2008; 299 (14): 1669–1677PubMedCrossRef

31.

Landry CS, Scoggins CR, McMaster KM, Martin RC Management of hepatic metastasis of gastrointestinal carcinoid tumors. J Surg Oncol 2008;97:253–258PubMedCrossRef

32.

Q. Chu, Hill H., Douglass H. et al. Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 2002; 9:855–862PubMedCrossRef

33.

Murthy R, Kamat P, Nunez R, et al. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol 2008; 19:145–151PubMedCrossRef

34.

Madoff DC, Gupta S, Ahrar K, et al. Update on the management of neuroendocrine hepatic metastases. J Vasc Interv Radiol 2006; 17:1235–1250PubMed

35.

Vogl TJ, Zangos S, Eichler K, Yakoub D, Nabil M Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfucion: an update. Eur Radiol 2007;17:1025–1034PubMedCrossRef

36.

Brown DB, Cardella JF, Sacks D, et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 2006; 17:225–232PubMed

37.

Fiorentini G, Aliberti C, Turrisi G, et al. Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. In Vivo 2007;21(6):1085–1091PubMed

38.

Giroux MF, Baum RA, Soulen MC. Chemoembolization of liver metastasis from breast carcinoma. J Vasc Interv Radiol 2004; 15:289–291PubMed

39.

Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative ocular melanoma study group report No. 26. Arch Ophthalmol 2005;123(12):1639–1643PubMedCrossRef

40.

Gragoudas ES, Egan KM, Seddon JM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology 1991;98(3):383–389PubMed

41.

Kath R, Hayungs J, Bornfeld N, et al. Prognosis and treatment of disseminated uveal melanoma. Cancer 1993;72(7):2219–2223PubMedCrossRef

42.

Malvigit GM, Charansangavej C, Carrasco CH, et al. Regression of ocular melanoma metastatic to the liver after hepatic artery chemoembolization with cisplatin and polyvinyl sponge. JAMA 1988; 260:974–976CrossRef

43.

Bedekian AY, Legha SS, Mavligit GM, et al. Treatment of uveal melanoma metastatic to the liver. A review of the M.D. Anderson Cancer Center experience and prognostic factors. Cancer 1995; 76:1665–1670CrossRef

44.

Sato T, Nathan FE, Berd D, et al. Lack of effects from chemoembolization for liver metastases from uveal melanoma (abstract). Proc Am Soc Clin Oncol 1995; 14:415

45.

Patel K, Sullivan K, Berd D, et al. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a Phase II study. Melanoma Res 2005;15:297–304PubMedCrossRef

46.

Sato T, Sullivan KL, Eschelman DJ, et al. Immunoembolization of malignant liver tumor with GM-CSF and ethiodized oil followed by gelatin sponge pledgets. The final results of a phase I/IIa study. J Clin Oncol 2005;23:16s–169s

47.

Burger I, Hong K, Schulick R, et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 2005; 16:353–361PubMed

48.

Herber S, Otto G, Schneider J, et al. Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Interv Radiol 2007;30:1156–1165CrossRef

49.

Patel NH, Hahn D, Rapp S, et al. Hepatic artery embolization: factors predisposing to postembolization pain and nausea. J Vasc Interv Radiol 2000; 11:453–460PubMedCrossRef

50.

Brown KT, Nevins AB, Getrajdman GI, et al. Particle embolization for hepatocellularcarcinoma. J Vasc Interv Radiol 1998;9:822–828PubMedCrossRef

51.

Chung J, Park J, Han J, et al. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996; 198:33–40PubMed

52.

Song S, Chung JW, Lim HJ, Park JH Nonhepatic arteries originating from the hepatic arteries: angiographic analysis in 250 patients. J Vasc Interv Radiol 2006; 17:461–469PubMedCrossRef

53.

Ibukuro K, Tsukiyama T, Mori K, Inoue Y Hepatic falciform ligament artery: angiographic anatomy and clinical importance. Surg Radiol Anat 1999; 20(5):367–371CrossRef

54.

Zhu LX, Meng XL, Fan ST. Elasticity of small artery in patient with spontaneous rupture of hepatocellular carcinoma. Hepatol Res 2004;29:13-17PubMedCrossRef

55.

Sakamoto I, Aso N, Nagaok i K, et al. Complications associated with transcatheter arterial embolization for hepatic tumours. Radiographics 1998;18:605–619PubMed

56.

Yu JS, Kim KW, Jeong MG, et al. Predisposing factors of bile duct injury after transcatheter arterial chemoembolization (TACE) for hepatic malignancy. Cardiovasc Intervent Radiol 2002; 25:270–274PubMedCrossRef

57.

Narendra Battula, Parthi Srinivasan, Mansoor Madanur, et al. Ruptured hepatocellular carcinoma following chemoembolization: a western experience. Hepatobiliary Pancreat Dis Int 2007; 6: 49–51PubMed

58.

Demachi H, Matsui O, Kawamori Y, et al. The protective effect of portoarterial shunts after experimental hepatic artery embolization in rats with liver cirrhosis. Cardiovasc Intervent Radiol. 1995;18(2):97–101PubMedCrossRef

59.

Kalva SP, Thabet A, Wicky S. Recent advances in transarterial therapy of primary and secondary liver malignancies. RadioGraphics 2008;28:101–117PubMedCrossRef

Title: Chemoembolization of hepatic malignancy
Authors: Carin F. Gonsalves
Daniel B. Brown
Publication date: 01-09-2009
Publisher: Springer-Verlag
Published in: Abdominal Radiology / Issue 5/2009
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-008-9446-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Chemoembolization of hepatic malignancy

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2009

Radiologic findings following Y90 radioembolization for primary liver malignancies

CT colonography: same-day tagging regimen with iodixanol and reduced cathartic preparation

Ablation of adrenal neoplasms

Transient hepatic attenuation difference (THAD) in biliary duct disease

Percutaneous image-guided radiofrequency ablation of liver tumors

Percutaneous image-guided therapy of intra-abdominal malignancy: imaging evaluation of treatment response

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page